New Blood Test May Predict Alzheimer's Years Before Symptoms Appear: Study Shows
Advertisement
Researchers have identified a blood marker that reflects the amount of Alzheimer's pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer's drugs.
Key points from the study:
The blood-based marker (P-tau217) may start to change several years before the onset of Alzheimer's symptoms. The marker can be measured using a simpler and cheaper analytical method.
Compared with a highly specialised analytical method, the fully automated method demonstrated a high level of accuracy.
The accuracy was over 90 percent regardless of age, gender, co-morbidity or whether the test is done in a specialist or primary care setting.
A multicentre study has now evaluated a simpler method of analysis for alzheimer’s disease. In total, 1,767 people with cognitive symptoms were included in the study.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.